I will be away from the site and Twitter stream (maybe...) for a few days so I will leave you with an extra-long biotech reading list so you don't get too restless.
If you enjoy these link-fests, there are many ways to access similar content and educational material:
(continue reading for full post)
If you enjoy these link-fests, there are many ways to access similar content and educational material:
- Check out the list of those I follow on Twitter @BioDueDiligence
- Sign up for the BiotechDueDiligence email newsletter to stay up-to-date with the latest content on the blog and website (goes out every 1-2 weeks)
- Explore a few new biotech blogs/writers/websites from the BiotechDueDiligence Links page
(continue reading for full post)
GlaxoSmithKline's CEO on the Price of New Drugs
Derek Lowe - In the Pipeline
Major trends in cancer drug development – Notes from TAT 2013
Ohad Hammer - ORF Blog
Eli Lilly, insurers at odds over new type of drug
IndyStar (local coverage of efforts by biotech/pharma players to hamper interchangable biosimilars at the state level)
The Rare Disease search engine that outperforms Google
MIT Technology Review
Hamburg Touts Regulatory Flexibility of Agency, Notes Upcoming Breakthrough Guidance
Regulatory Affairs Professional Society (RAPS)
A coming of age for PacBio and longread sequencing? #AGBT2013
LabSpaces
Biosimilars: Not so far so fast
GEN
How much is your IND going to cost?
Pharma Directions
Fighting a Global War on Rare Diseases
Xconomy - Francois Nader (NPSP)
How fresh is big pharma's "freshness index" ?
Bernard Munos (Forbes)
How much bipharma revenue comes from relatively new drugs vs old drugs approved long ago? The answer may surprise you.
Derek Lowe - In the Pipeline
Major trends in cancer drug development – Notes from TAT 2013
Ohad Hammer - ORF Blog
Eli Lilly, insurers at odds over new type of drug
IndyStar (local coverage of efforts by biotech/pharma players to hamper interchangable biosimilars at the state level)
The Rare Disease search engine that outperforms Google
MIT Technology Review
Hamburg Touts Regulatory Flexibility of Agency, Notes Upcoming Breakthrough Guidance
Regulatory Affairs Professional Society (RAPS)
A coming of age for PacBio and longread sequencing? #AGBT2013
LabSpaces
Biosimilars: Not so far so fast
GEN
How much is your IND going to cost?
Pharma Directions
Fighting a Global War on Rare Diseases
Xconomy - Francois Nader (NPSP)
How fresh is big pharma's "freshness index" ?
Bernard Munos (Forbes)
How much bipharma revenue comes from relatively new drugs vs old drugs approved long ago? The answer may surprise you.
RSS Feed
